PUBLISHER: TechNavio | PRODUCT CODE: 1911214
PUBLISHER: TechNavio | PRODUCT CODE: 1911214
The global non-alcoholic steatohepatitis (nash) market is forecasted to grow by USD 40056.2 mn during 2025-2030, accelerating at a CAGR of 47.1% during the forecast period. The report on the global non-alcoholic steatohepatitis (nash) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of obesity and metabolic syndrome, rise in global aging population, advancements in diagnostic technologies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 41.3% |
| CAGR | 47.1% |
| Incremental Value | $40056.2 mn |
Technavio's global non-alcoholic steatohepatitis (nash) market is segmented as below:
By Distribution Channel
By Application
By Product
Geography
This study identifies the rising patient engagement and education as one of the prime reasons driving the global non-alcoholic steatohepatitis (nash) market growth during the next few years. Also, emergence of combination therapies and integration of digital health solutions will lead to sizable demand in the market.
The report on the global non-alcoholic steatohepatitis (nash) market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global non-alcoholic steatohepatitis (nash) market vendors that include AbbVie Inc., Bristol Myers Squibb Co., Cirius Therapeutics, Eli Lilly and Co., Enanta Pharmaceuticals Inc., Enzo Biochem Inc., GENFIT SA, Gilead Sciences Inc., Intercept Pharmaceuticals Inc., Inventiva S.A., Madrigal Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Prometheus Laboratories, Siemens Healthineers AG, Takeda Pharmaceutical Ltd., Zydus Lifesciences Ltd.. Also, the global non-alcoholic steatohepatitis (nash) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.